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ORIGINAL RESEARCH

Association Between Modiﬁable Risk Factors and Pharmaceutical
Expenditures Among Adults With Atherosclerotic Cardiovascular
Disease in the United States: 2012–2013 Medical Expenditures
Panel Survey
Joseph A. Salami, MD, MPH; Javier Valero-Elizondo, MD, MPH; Oluseye Ogunmoroti, MD, MPH; Erica S. Spatz, MD, MHS;
Jamal S. Rana, MD, PhD; Salim S. Virani, MD, PhD; Ron Blankstein, MD; Adnan Younus, MD; Alejandro Arrieta, PhD;
Michael J. Blaha, MD, MPH; Emir Veledar, PhD; Khurram Nasir, MD, MPH

Background-—Atherosclerotic cardiovascular disease (ASCVD) causes most deaths in the United States and accounts for the
highest healthcare spending. The association between the modiﬁable risk factors (MRFs) of ASCVD and pharmaceutical
expenditures are largely unknown.
Methods and Results-—We examined the association between MRFs and pharmaceutical expenditures among adults with ASCVD
using the 2012 and 2013 Medical Expenditure Panel Survey. A 2-part model was used while accounting for the survey’s complex
design to obtain nationally representative results. All costs were adjusted to 2013 US dollars using the gross domestic product
deﬂator. The annual total pharmaceutical expenditure among those with ASCVD was $71.6 billion, 33% of which was for
medications for cardiovascular disease and 14% medications for diabetes mellitus. The adjusted relationship between MRFs and
pharmaceutical expenditures showed signiﬁcant marginal increase in average annual pharmaceutical expenditure associated with
inadequate physical activity ($519 [95% conﬁdence interval (CI), $12–918; P=0.011]), dyslipidemia ($631 [95% CI, $168–1094;
P=0.008]), hypertension: ($1078 [95% CI, $697–1460; P<0.001)], and diabetes mellitus ($2006 [95% CI, $1470–2542]). Compared
with those with optimal MRFs (0–1), those with average MRFs (2–3) spent an average of $1184 (95% CI, $805–1564; P<0.001)
more on medications, and those with poor MRFs (≥4) spent $2823 (95% CI, $2338–3307; P<0.001) more.
Conclusions-—Worsening MRFs were proportionally associated with higher annual pharmaceutical expenditures among patients
with established ASCVD regardless of non-ASCVD comorbidity. In-depth studies of the roles played by other factors in this
association can help reduce medication-related expenditures among ASCVD patients. ( J Am Heart Assoc. 2017;6:e004996.
DOI: 10.1161/JAHA.116.004996.)
Key Words: coronary heart disease • cost • modiﬁable risk factors • pharmaceutical expenditure

C

ardiovascular disease (CVD) remains the leading cause
of morbidity and mortality globally,1 and atherosclerotic
cardiovascular disease (ASCVD) is the most common type,

accounting for >370 000 deaths annually.2 In addition to the
impact on mortality, ASCVD causes signiﬁcant loss of quality
of life and is responsible for the highest healthcare
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Methods

larger and analyzable population of adults with ASCVD. Race
and ethnicity were determined using the MEPS-deﬁned
categories that allow respondents to report multiple Hispanic
ethnicities.
Because MEPS consists of publicly available, de-identiﬁed
data ﬁles, this study was exempt from institutional review
board, in accordance with US Department of Health and
Human Services guidelines. Written consent was obtained
from participants to contact them for interviews and to
contact their healthcare providers (clinicians and pharmacies).
We classiﬁed participants as having ASCVD using the
International Statistical Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation (ICD-9 CM) diagnosis of the
condition (Table S1)16,17 and/or self-reported history of
diagnosis of coronary heart disease, angina, myocardial
infarction, and/or stroke. Our study population was limited
to noninstitutionalized US adults with established ASCVD who
were ≥40 years at the time of the survey (ASCVD is
uncommon among younger adults), had a body mass index
(calculated as weight in kilograms divided by height in meters
squared) of ≥18.5 kg/m2 (underweight individuals generally
represent a sicker population),18 and who had a ﬁnal personweight >0 to be representative of the national population at
the time of the survey (Figure S1).

Study Design and Population
We conducted a retrospective study of US adults aged
≥40 years with established ASCVD using data from the 2012
and 2013 Medical Expenditure Panel Survey (MEPS) database.
MEPS, sponsored by the Agency for Healthcare Research and
Quality (AHRQ), is a national survey of individuals, families,
their medical providers (for medical conditions), and employers, to obtain patients’ healthcare resource utilization and
expenditure. Each year, the MEPS Household Components
(MEPS-HC) sample is drawn from respondents of the previous
year’s National Health Interview Survey. It has an overlapping
panel design, with each panel composed of randomly sampled
noninstitutionalized US civilians. Participants are interviewed
every 6 months over a period of 30 months, and their
responses are reported annually to provide nationally representative estimates of sociodemographic characteristics,
medical conditions, and healthcare utilization and costs.11,12
Interviews were conducted over the telephone with participants, and their physicians, hospitals, and pharmacies were
contacted to obtain additional healthcare use and cost data.
The AHRQ researchers assigned person weights and variance
estimation strata to participants after data collection to
reﬂect survey nonresponse and population totals of the
participants surveyed.13
We merged the MEPS-HC full-year consolidated, medical
conditions, and prescribed medicines ﬁles for 2012 and 2013
for this study.14,15 Pooling this 2-year data afforded us a
DOI: 10.1161/JAHA.116.004996

Pharmaceutical Expenditures
During the household interview, respondents supplied the
name of any prescribed medicine that they or their family
members purchased or otherwise obtained during the reference period. They were also asked for permission to obtain
payment data and other information from pharmacies. With
the written permission from participants, pharmacies were
contacted to obtain information on the medication name,
national drug code, strength, quantity, date ﬁlled, and amount
paid. The multisourced, person-level medication information
was then included in MEPS prescribed medicine ﬁles and
linked to the Multum Lexicon databases by AHRQ researchers
to assign the drugs into classes.19 The codes we used to
group CVD, diabetes, and other classes of medications are
shown in Table S2. More details on the collection and
management of pharmaceutical data in MEPS are provided
elsewhere.20 For each drug prescribed, the exact dollar
amount paid was reported. Using these cost data, we
calculated expenditures speciﬁc to the different classes of
drugs. All expenditures were adjusted to constant 2013 US
dollars using the gross domestic product deﬂator.

Modiﬁable Risk Factors and Comorbidity Burden
The MRFs examined in this study included inadequate
physical
activity,
obesity,
smoking,
dyslipidemia,
Journal of the American Heart Association
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expenditure for any single class of disease.1 In 2011, the
estimated annual direct cost for CVD and stroke in the United
States was about $196 billion.1 Incidence, associated morbidity, disability, mortality, and healthcare costs have been
shown to depend largely on modiﬁable risk factors (MRFs) for
CVD.3–6
Expenditures on prescription medication in the US general
population formed 9.8% of total healthcare spending in 2014,7
and in 2012, 26.1% of total healthcare expenditures among
adults with CVD were for medications.8 Although few studies
have reported incremental healthcare costs associated with
worsening cardiovascular risk factor proﬁles among patients
with diagnosed CVD,9,10 the association between MRFs and
pharmaceutical expenditures in the United States has not
been examined.
Considering the economic impact of ASCVD and the
signiﬁcant contribution of pharmaceutical expenditure to
overall healthcare expenditure, we aimed to examine the
association between MRFs and pharmaceutical expenditures
(both overall and medication-speciﬁc) in a nationally representative population with established ASCVD.

Risk Factors and Pharmaceutical Expenditures

Salami et al

Covariates
We considered age, sex, race/ethnicity, and family income as
factors that were also associated with pharmaceutical
expenditures; therefore, we used these as covariates in the
determination of the association between MRFs and pharmaceutical expenditures. Participant age as of the last day of the
survey was classiﬁed into 3 categories: 40 to 64, 65 to 74,
and ≥75 years. We had 5 categories of race and ethnicity:
non-Hispanic white, non-Hispanic black, Hispanic, Asian, and
other (American Indian, Alaska Native, and those who
reported multiple races/ethnicities). There were 4 categories
of family income level expressed as a proportion of the federal
poverty level: <100%, 100% to 200%, 200% to 400%, and
≥400%.

Statistical Analysis
All analyses were conducted using STATA 14 (StataCorp). We
accounted for the complex sampling design of MEPS in all our
analyses using the ﬁnal person-weight and variance estimations (person sampling and strata). We determined the
prevalence of each MRF and of the 3 MRF proﬁles and used
v2 statistics to test for their variations across different
DOI: 10.1161/JAHA.116.004996

sociodemographic characteristics. Because the distribution of
cost data is often right-skewed secondary to the high
proportion of people with no expenditure, we used a 2-part
model to estimate the marginal pharmaceutical expenditure
associated with each MRF (unfavorable versus favorable), the
3 MRF proﬁles, and the modiﬁed GCCI. The 2-part model
consists of (1) a binary choice model ﬁt for the probability of
observing a positive-versus-zero annual expenditure on medications using the probit command and (2), contingent on
having >$0 annual pharmaceutical expenditure, a generalized
linear model (with c distribution and a log link) was ﬁtted for
the >$0 expenditure to estimate the effect of MRFs on
pharmaceutical expenditures.23,24 To determine the appropriate distribution of the generalized linear model in the 2-part
model, we used the modiﬁed Park test.25 We used the margins
postestimation command to determine the marginal and
absolute pharmaceutical expenditures associated with the
predictor variables in the 2-part model. The use of the 2-part
model and the margins in STATA allowed us to estimate
robust standard errors, 95% conﬁdence intervals (CIs) and P
values associated with each estimate of marginal expenditure
(a level of signiﬁcance was 0.05). This also helped avoid the
difﬁculties associated with retransformation when ordinary
least squares with the log scale was used in analyzing highly
skewed expenditure data such as MEPS. In addition, because
the svy: twopm command can be used in STATA to incorporate
the complex design of MEPS in our analyses, our results can
be generalizable to the US population. However, the 2-part
model did not cause the data to become normal; the
skewness and kurtosis tests for normality among those with
positive cost value (ie, cost >0$) showed the distribution is
nonnormal (joint P<0.001).

Results
Sample Characteristics
From 2012 to 2013, there were 75 914 respondents in
MEPS, representing an average annual national estimate of
314.6 million individuals—similar to the average of the
projected US civilian population of 2012 and 2013. Among
this surveyed population, 4248 adults aged ≥40 years with a
BMI ≥18 had ASCVD (an annual equivalent of 21.9 million US
adults). The mean age was 67.7 years (SD 21.6), and 44.8%
were female.
The distribution of demographic characteristics for the
study population is shown in Table S3. The prevalence and the
variation of the prevalence of each MRF are shown in Table 1.
Hypertension was the most common MRF among ASCVD
adults, with a prevalence of 81.5%. Smoking and obesity were
signiﬁcantly more prevalent among adults aged 40 to
65 years, whereas the prevalence of dyslipidemia was higher
Journal of the American Heart Association
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hypertension, and diabetes mellitus. We used responses from
the self-administered questionnaire to determine the MRF
status of participants, and we classiﬁed each as a binary
variable (favorable [0] versus unfavorable [1]). Any participant
who did not engage in moderate vigorous physical activity 5
times a week; had a BMI ≥30 kg/m2; was a smoker at the time
of interview; or reported a diagnosis of a cholesterol disorder,
hypertension, or diabetes mellitus was classiﬁed as having
unfavorable MRFs. Based on the presence of these individual
risk factors, survey participants were categorized as poor (≥4
cardiovascular risk factors), average (2–3 cardiovascular risk
factors), or optimal (0–1 cardiovascular risk factor). We also
determined the contribution of comorbidity to the association
between MRFs and pharmaceutical expenditures and compared the marginal pharmaceutical expenditures associated
with comorbidity and those associated with MRF proﬁle.
Participants’ comorbidity burden was assessed using the
grouped Charlson Comorbidity Index (GCCI), which has been
described elsewhere.21,22 For our analyses, however, we
modiﬁed the GCCI by excluding acute myocardial infarction,
congestive heart failure and peripheral vascular disease from
our estimation of GCCI score, since these were included in our
deﬁnition of ASCVD; and diabetes mellitus, since it was
considered a cardiovascular risk factor. We had 3 categories
for GCCI: no comorbidity (0), 1 long-term condition (1), and ≥2
long-term conditions present other than CVD and/or diabetes
mellitus (2; Table S2).

DOI: 10.1161/JAHA.116.004996

1203

1398

65–79

≥80

1903

Women

1027

1185

1390

100–200%

200–400%

>400%

Smoking

15.6 (11.6–20.8)
0.026†

74.5 (68.6–79.6)
<0.001†

515

2

Obesity

<0.001†

44.3 (38.5–50.3)

45.8 (40.9–50.7)

36.2 (33.6–38.8)

0.146

36.8 (33.0–40.8)

42.2 (37.9–46.6)

37.8 (33.9–41.8)

40.5 (36.6–44.6)

<0.001

†

38.3 (26.2–52.0)

47.7 (42.8–52.6)

8.6 (4.6–15.4)

48.6 (43.6–53.6)

37.7 (35.0–40.5)

0.945

9.2 (36.1–42.4)

39.1 (35.8–42.4)

<0.001

†

26.0 (22.3–30.0)

41.5 (37.3–45.9)

48.5 (45.1–52.0)

39.1 (36.8–41.5)

Hyperlipidemia

0.007†

84.0 (79.5–87.6)

78.8 (74.2–82.8)

75.3 (72.9–77.6)

0.960

77.4 (74.1–80.5)

76.5 (72.2–80.3)

76.8 (73.3–80.0)

77.9 (73.2–81.9)

<0.001

†

79.3 (68.5–87.1)

70.4 (66.0–74.5)

81.7 (73.0–88.0)

69.4 (65.5–73.1)

78.8 (76.3–81.1)

<0.001

†

73.0 (69.8–76.0)

80.4 (77.8–82.7)

<0.001

†

76.4 (72.3–80.2)

85.9 (82.4–88.8)

71.2 (68.4–73.8)

77.1 (75.1–79.0)

ASCVD indicates atherosclerotic cardiovascular disease; CI, conﬁdence interval; GCCI, grouped Charlson Comorbidity Index; MEPS, Medical Expenditure Panel Survey.
*v2 Statistic used to test difference in proportions between respondents.
†
Statistically signiﬁcant.
‡
Family income expressed as a proportion of the federal poverty level.

P value

20.9 (17.4–24.9)

69.0 (64.8–72.9)

867

1

15.4 (13.4–17.8)

2866

63.3 (60.7–65.9)

<0.001

†

<0.001

12.7 (10.0–15.9)

†

13.6 (10.8–17.1)

17.4 (14.7–20.4)

28.9 (24.7–33.6)

0.001

†

17.8 (9.9–29.9)

10.9 (7.7–15.3)

5.3 (2.4–11.4)

20.0 (16.7–23.7)

17.0 (15.0–19.3)

0.014

†

14.5 (12.3–17.0)

18.2 (15.9–20.8)

<0.001

†

4.4 (3.2–6.0)

14.3 (11.6–17.5)

28.5 (25.3–32.0)

16.6 (14.8–18.5)

59.0 (55.0–62.9)

67.6 (64.1–70.9)

69.1 (65.0–72.9)

72.2 (67.5–76.5)

0.008

†

76.5 (66.7–84.1)

69.4 (64.3–74.0)

58.8 (47.8–69.0

70.5 (66.7–74.1)

64.7 (61.9–67.3)

<0.001

†

71.0 (68.0–73.8)

61.7 (58.8–64.5)

<0.001

†

73.6 (69.9–77.0)

59.7 (55.6–63.7)

63.7(60.4–66.9)

65.8 (63.6–68.0)

Inadequate Physical Activity

0

GCCI

P value

646

<100%

Family income level

‡

90

Other

P value

107

375

Hispanic

485

Non-Hispanic black

Asian

3191

Non-Hispanic white

Race/ethnicity

P value

2345

Men

Sex

P value*

1647

4248

40–64

Age group, y

Overall

Prevalence, % (95% CI)

0.003

86.0 (80.0–90.4)

86.4 (82.6–89.5)

79.2 (77.1–81.2)

<0.001

†

77.1 (73.1–80.6)

82.0 (79.2–84.5)

86.3 (83.3–88.7)

82.6 (78.6–86.0)

0.004

†

82.2 (69.4–90.4)

80.8 (76.9–84.2)

78.7 (68.4–86.4)

88.9 (85.7–91.5)

80.5 (78.5–82.4)

0.273

80.4 (77.9–82.7)

82.4 (79.9–84.6)

<0.001

†

85.5 (82.8–87.9)

85.7 (81.8–88.9)

75.0 (72.0–77.8)

81.5 (79.8–83.1)

Hypertension

0.004†

40.3 (33.4–47.6)

36.8 (32.5–41.4)

30.5 (28.1–32.9)

0.212

30.1 (26.2–34.3)

33.5 (29.9–37.3)

35.0 (31.4–38.9)

34.9 (30.5–39.4)

<0.001†

63.2 (47.8–76.3)

45.1 (40.6–49.8)

46.1 (37.0–55.5)

40.7 (36.7–44.7)

29.1 (26.5–31.8)

0.708

32.5 (29.5–35.7)

33.3 (30.4–36.4)

0.024†

30.1 (26.9–33.6)

37.0 (33.0–41.2)

32.5 (29.5–35.6)

33.0 (30.9–35.1)

Diabetes Mellitus
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Table 1. Prevalence of Individual Modiﬁable Risk Factors Across Sociodemographic Characteristics of Adults Aged ≥40 Years Living With ASCVD, MEPS 2012–2013
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Annual Pharmaceutical Expenditures Among
Those With ASCVD
Of the 4248 adults with ASCVD in 2012–2013, 95.4% used
prescription medications; 86.8% used ≥1 CVD medication. The
annual per capita pharmaceutical expenditures among adults
with ASCVD was $3432. On average, 34% of total pharmaceutical expenditure was spent on CVD medications ($1139; 95%
CI, $1063–1215), and 14% ($482; 95% CI, $407–556) was
spent on antidiabetic medications. The residual 52% ($1786)
was for medications other than those for CVD and diabetes
(Figure 1). When projected using MEPS’s complex designs, the
2012–2013 annual total pharmaceutical spending among
those with ASCVD was an estimated $71.6 billion; $23.8 billion was spent on CVD medications, $10 billion was spent on
diabetes medications, and approximately $37.8 billion was
spent on other medications.

Effects of MRFs on Annul Pharmaceutical
Expenditures Among Those With ASCVD
The unadjusted and adjusted marginal pharmaceutical expenditures associated with the presence versus absence of
individual MRFs is shown in Table 2. Inadequate physical
activity, dyslipidemia, hypertension, and diabetes mellitus
were statistically signiﬁcantly associated with total pharmaceutical expenditure after adjusting for sociodemographic
characteristics and burden of comorbid conditions. The
marginal pharmaceutical expenditure associated with diabetes mellitus was the highest of all MRFs at $2006 (95% CI,
$1470–$2542; P<0.001). When different categories of medication expenditures were examined, dyslipidemia, hypertension, and diabetes mellitus were signiﬁcantly associated with
increased CVD medication expenditures; obesity and diabetes
mellitus were associated with increased expenditures for
diabetes medication; and inadequate physical activity and
hypertension were signiﬁcantly associated with an increase in
non-CVD, nondiabetic medication expenditures.
The average annual pharmaceutical expenditure among
patients with ASCVD who had an optimal MRF proﬁle was
$1400 (95% CI, $1073–1728) compared with $2672 (95% CI,
$2332–3013) among those with an average MRF proﬁle and
$4516 (95% CI, $4067–4965) among those with a poor MRF

$25
$20
$23
$184
$287

Psychotherapeutic Medications
CNS Medications

$343
$1,139 (34%)

RS Medications
GI Medications
Homorne Modifiers

$301

$1,786 (52%)

Immunologic Drugs
Anti-Neoplastic Medications
Anti-infective Medications
Rheumatologic Medications
Miscellaneous Medications

$482 (14%)

$382

$185
$77
$119
$44
$100
$84

Other CVD medications
Anti-arrhythmias
Anti-anginas
Coagulation Modifiers
Antihypertensives
Anti-hyperlipidimeias

CVD Agents
Anti-Diabetes Agents

$403
Others Medications

$341

Other Medications
CVD Medications

Figure 1. Annual per capita pharmaceutical expenditures for different medication classes among adults with ASCVD, MEPS 2012–2013. All
costs are in 2013 US dollars. ASCVD indicates atherosclerotic cardiovascular disease; CNS, central nervous system; CVD, central nervous
system; GI, gastrointestinal; MEPS, Medical Expenditure Panel Survey; RS, respiratory system.
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among those aged 65 to 79 years; men were more likely to
have hyperlipidemia than women. Most of the study participants (49.9%) reported an average MRF proﬁle, and with the
exception of sex, there was signiﬁcant variation in the
prevalence of MRF proﬁles across different sociodemographic
characteristics (Table S4).

DOI: 10.1161/JAHA.116.004996

1679 (1261–2096)
2557 (1997–3117)

Hypertension vs no hypertension

Diabetes mellitus vs no diabetes mellitus

223 (74–3730
65 ( 148 to 278)
649 (502–795)
574 (426–723)
357 (202–512)

Obesity vs normal BMI

Currently smoking vs nonsmoker

Dyslipidemia vs no dyslipidemia

Hypertension vs no hypertension

Diabetes mellitus vs no diabetes mellitus

502 (315–688)
53 ( 171 to 2765)
168 (10–325)
311 (153–469)
1399 (1193–1606)

Obesity vs normal BMI

Currently smoking vs nonsmoker

Dyslipidemia vs no dyslipidemia

Hypertension vs no hypertension

Diabetes mellitus vs no diabetes mellitus

520 (61–979)
776 (187–1366)
22 ( 614 to 658)
626 (314–938)
697 (275–1120)

Obesity vs normal BMI

Currently smoking vs nonsmoker

Dyslipidemia vs no dyslipidemia

Hypertension vs no hypertension

Diabetes mellitus vs no diabetes mellitus

406 (254–557)

<0.001‡

<0.001

324 ( 181 to 828)

0.01‡

0.001‡

<0.001

611 (242–979)

604 (329–878)

160 ( 296 to 616)

340 ( 25 to 704)

0.027‡

0.946

480 (135–825)

1540 (1145–1934)

328 (198–459)

178 (23–333)

15 ( 213 to 183)

476 (297–656)

0.063

‡

‡

<0.001

‡
‡

0.037

0.643

<0.001

‡

255 (121–388)

567 (420–715)

<0.001‡

<0.001‡

145 ( 73 to 363)
631 (489–774)

<0.001‡

272 (123–422)

0.551

0.004

142 ( 8 to 291)

2564 (2020–3108)

<0.001‡

‡

1679 (1302–2056)

<0.001‡

0.123

1143 (627–1659)

411 ( 267 to 1090)

0.002‡

0.007

1146 (675–1616)

<0.001‡
‡

893 (430–1355)

Marginal Expenditures (95% CI)

0.001‡

P Value

Model 1*

‡

0.001‡

<0.001

0.490

0.207

0.068

0.007‡

<0.001

<0.001

0.024

0.882

<0.001

‡

‡

‡

‡

<0.001‡

<0.001‡

<0.001‡

<0.001‡

0.190

<0.001

0.063

<0.001‡

<0.001‡

<0.001‡

0.233

<0.001‡

<0.001‡

P Value

386 (13–759)

492 (219–765)

144 ( 568 to 280)

240 ( 248 to 728)

77 ( 315 to 469)

319 (16–622)

1296 (1108–1484)

77 ( 75 to 228)

40 ( 194 to 114)

116 ( 80 to 312)

227 (94–360)

10 1 ( 23 to 226)

235 (77–393)

394 (230–558)

506 (350–663)

81 ( 111 to 273)

141 ( 24 to 305)

73 ( 76 to 222)

2006 (1470–2542)

1079 (697–1460)

631 (168–1094)

400 ( 237 to 1037)

349 ( 106 to 8030

520 (121–918)

Marginal Expenditures (95% CI)

Model 2†

All cost are in 2013 US dollars. BMI indicates body mass index; CI, conﬁdence interval; CVD, cardiovascular disease; MEPS, Medical Expenditure Panel Survey; MRF, modiﬁable risk factor.
*Model 1: Each MRF was used as a predictor and adjusted for age, sex, race/ethnicity, and income level (all variable entered as categorical variables).
†
Model 2: All MRFs were entered simultaneously and adjusted for age, sex, race/ethnicity, income level, and Charlson Comorbidity Index (all variables entered as categorical variables).
‡
Statistically signiﬁcant.

443 ( 25 to 911)

Inadequate vs optimal physical activity

Other medication expenditures

253 (120–386)

Inadequate vs optimal physical activity

Diabetes medication expenditures

118 ( 32 to 268)

Inadequate vs optimal physical activity

CVD medication expenditures

719 (29–1409)
1031 (396–1666)

Currently smoking vs nonsmoker

1271 (726–1817)

Obesity vs normal BMI

Dyslipidemia vs no dyslipidemia

864 (336–1391)

Marginal Expenditures (95% CI)

Inadequate vs optimal physical activity

Overall pharmaceutical expenditures

MRF

Univariate (Unadjusted)

0.042‡

<0.001‡

0.504

0.333

0.698

0.039‡

<0.001‡

0.320

0.608

0.245

0.001‡

0.110

0.004‡

<0.001‡

<0.001‡

0.408

0.093

0.333

<0.001‡

<0.001‡

0.008‡

0.217

0.132

0.011‡

P Value
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Table 2. Marginal Pharmaceutical Expenditures Associated With Each MRF: Results From the 2-Part Econometric Model, MEPS 2012–2013
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Table 3. Per Capita Marginal Pharmaceutical Expenditures Associated With Grouped MRFs and Charlson Comorbidity Index
Among Adults With ASCVD, MEPS 2012–2013
MRF Proﬁle

Unadjusted

Adjusted*

†

Overall pharmaceutical expenditures (95% CI)
Optimal MRF

Reference

P value

Reference

P-value

Average MRF

1272 (844–1700)

<0.001‡

1184 (804–1564)

<0.001‡

Poor MRF

3115 (2645–3586)

<0.001‡

2823 (2338–3308)

<0.001‡

P value

Reference

P value

406 (231–582)

<0.001‡

CVD-medication expenditures (95% CI)
Optimal MRF

Reference

‡

Average MRF

396 (200–591)

<0.001

Poor MRF

791 (589–993)

<0.001‡

848 (653–1043)

<0.001‡

P value

Reference

P value

131 (77–185)

<0.001‡

Diabetes medication expenditures (95% CI)
Optimal MRF

Reference

‡

Average MRF

136 (84–188)

<0.001

Poor MRF

969 (797–1141)

<0.001‡

943 (760–1126)

<0.001‡

P value

Reference

P value

526 (134–918)

0.009‡

807 (434–1180)

<0.001‡

Other medication expenditures (95% CI)
Optimal MRF

Reference

‡

Average MRF

622 (199–1045)

0.004

Poor MRF

1167 (773–1560)

<0.001‡

Modiﬁed Grouped CCI

Adjusted§

Unadjusted
†

Overall pharmaceutical expenditures (95% CI)
0

Reference

P value
‡

Reference

P value

2272 (1519–3025)

<0.001‡

1

2603 (1723–3483)

<0.001

2

2518 (1665–3371)

<0.001‡

2068 (1349–2787)

<0.001‡

P value

Reference

P value

CVD-medication expenditures (95% CI)
0
1
2

Reference
53 ( 130 to 236)
132 ( 70 to 334)

0.567

21 ( 153 to 195)

0.811

0.2‡

30 ( 169 to 229)

0.77

Diabetes medication expenditures (95% CI)
0

Reference

P value

Reference

P value

1

159 (21–297)

<0.024‡

29 ( 101 to 160)

<0.001‡

2

375 (94–656)

0.009‡

206 (1–411)

0.048

Reference

P value

2015 (1412–2617)

<0.001‡

1773 (1189–2357)

<0.001‡

Other medication expenditures (95% CI)
0

Reference

P value
‡

1

2312 (1514–3111)

<0.001

2

1903 (1274–2532)

<0.001‡

All costs are in 2013 US dollars. ASCVD indicates atherosclerotic cardiovascular disease; CCI, Charlson Comorbidity Index; CI, conﬁdence interval; CVD, cardiovascular disease; MRF,
modiﬁable risk factors; MEPS, Medical Expenditure Panel Survey.
*Adjusted for age, sex, race/ethnicity, income level, CCI.
†
All Costs are in 2013 USD.
‡
Statistically signiﬁcant.
§
Adjusted for age, sex, race/ethnicity, income level, and grouped MRFs category.
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expenditure was $1184 (95% CI, $805–1564) higher among
those with average MRF proﬁles and $2823 (95% CI, $2338–
3307) higher among ASCVD patients with poor MRF proﬁles
compared with those with optimal MRF proﬁles (P<0.001).

proﬁle. The unadjusted and adjusted marginal pharmaceutical
expenditures associated with MRF proﬁles are shown in
Table 3. After accounting for demographics, income status,
and comorbid conditions, the annual pharmaceutical
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Discussion
In a nationally representative population, our study demonstrated that in 2012–2013, adults with established ASCVD
spent $284 billion on health care per annum. Of this,
$71.6 billion was spent on medications. The contributions

$7,000

Mean Pharmaceu
utical Expenditurees

$6,000

$5,000

$4,000
CVD Medications
Diabetes Medications

$3,000

Other Medications
$2,000

$1,000

$$-

Optimal
MRF

CVD Medications

$662

Average
MRF
CCI = 0
$1,003

Poor MRF

Optimal
MRF

$1,395

$514

Average
MRF
CCI = 1
$1,008

Poor MRF

Optimal
MRF

$1,416

$261

Average
MRF
CCI = 2
$1,087

Diabetes Medications

$13

$151

$869

$36

$146

$1,012

$-

$179

$1,414

Other Medications

$708

$950

$1,323

$1,965

$3,586

$3,440

$1,891

$2,582

$3,407

Poor MRF

$1,454

Figure 2. Mean pharmaceutical expenditures associated with grouped MRFs across different levels of grouped CCI among those with ASCVD,
MEPS 2012–2013. Mean expenditures were estimated using the person weight and variance estimation stratum and person sampling unit of
MEPS 2012–2013. All costs are in 2013 US dollars. ASCVD indicates atherosclerotic cardiovascular disease; CCI, Charlson Comorbidity Index;
CVD, cardiovascular disease; MEPS, Medical Expenditure Panel Survey; MRF, modiﬁable risk factor.
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of medications for CVD and diabetes mellitus to the overall
pharmaceutical expenditures were $23.8 billion (34%) and
$10 billion (14%), respectively. More than half (52%) of the
overall pharmaceutical expenditure was spent on non-CVD,
nondiabetes medications. The details of the 2012–2013 per
capita pharmaceutical expenditures examined in the context
of the mean healthcare expenditures in our study population
are shown in Figure S2. The overall pharmaceutical expenditure was signiﬁcantly associated with individual MRFs;
inadequate physical activity, dyslipidemia, hypertension, and
diabetes mellitus as well as worsening MRF proﬁle were all
associated with higher pharmaceutical expenditure. Similar
patterns were observed when expenditures for speciﬁc
medication classes (CVD, diabetes, and others) were examined. These associations persisted even after accounting for
underlying comorbid conditions.
Many studies have found that current MRFs are important
drivers of future morbidity and mortality among individuals
with established CVD in a dose-response fashion.26–28
Although studies within and outside the United States have
attempted to estimate the incremental healthcare expenditures associated with individual cardiovascular MRFs among
those without established CVD,29,30 no study has detailed the
potential economic impact of CVD MRFs on pharmaceutical

Similar trends were noted when mean expenditures for
speciﬁc medication classes (CVD, diabetes, and other) were
considered.
Figure 2 describes the association among both MRF
proﬁles and increasing burden of comorbid conditions with
annual pharmaceutical expenditures (overall and medicationspeciﬁc). The lowest annual drug costs were observed among
those with optimal MRF proﬁles and no major comorbid
conditions ($1386). In contrast, ASCVD patients with poor
MRF proﬁles and a GCCI of 2 had the highest annual
pharmaceutical expenditures ($6948). Across worsening
comorbidity, individuals with poor MRF proﬁles incurred the
highest pharmaceutical expenditures (Figure 2). In a subanalysis of speciﬁc CVD medications, annual costs of antihyperlipidemics, antihypertensives, and coagulation modiﬁers
signiﬁcantly increased with worsening MRF proﬁle across all
categories of comorbidity burden (Figure 3).
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$1,600

$1,400

Mean Pharmaceutical Expenditures

$1,200

$1,000

$800
Other CVD medications
Anti-arrhythmias

$600

Anti-anginas
Coagulation Modifiers

$400

Antihypertensives
Anti-hyperlipidimeias
A ti h
li idi i

$200

$-

Optimal
MRF

Other CVD medications
Anti-arrhythmias
Anti-anginas
Coagulation Modifiers
Antihypertensives
Anti-hyperlipidimeias

$1
$26
$7
$279
$147
$202

Average
MRF
CCI = 0
$13
$17
$22
$264
$341
$345

Poor MRF

Optimal
MRF

$25
$13
$29
$345
$455
$528

$2
$5
$$98
$189
$220

Average
MRF
CCI = 1
$98
$13
$18
$231
$357
$291

Poor MRF

Optimal
MRF

$38
$36
$45
$301
$433
$563

$$195
$1
$11
$54
$1

Average
MRF
CCI = 2
$7
$33
$12
$290
$418
$327

Poor MRF

$20
$27
$7
$313
$575
$512

Figure 3. Mean CVD medication expenditures and their association with MRF proﬁles across different levels of grouped CCI among those with
ASCVD, MEPS 2012–2013. Mean expenditures were estimated using the person weight, variance estimation stratum, and person sampling unit
of MEPS 2013. All costs are in 2013 US dollars. ASCVD indicates atherosclerotic cardiovascular diseases; CCI, Charlson Comorbidity Index;
CVD, cardiovascular disease; MEPS, Medical Expenditure Panel Survey; MRF, modiﬁable risk factor.

costs, which remains one of the largest contributors to overall
healthcare expenditures. Sullivan et al showed that among
persons with cardiometabolic risk factor clusters (BMI ≥25
and any 2 of hypertension, hyperlipidemia, and diabetes
mellitus), 34% of total healthcare expenditure was for
prescription medications in 2006,10 and depending on the
source of payment, the proportion could be as high as 49%.8
In Australia, Ademi et al showed that obesity, hypertension,
and diabetes mellitus are predictors of higher pharmaceutical
expenditures among persons with or at risk of CVD.29
The ﬁndings of Ademi et al are similar to ours. Our study of
the US adults with ASCVD in 2012–2013 showed that
individual cardiovascular MRFs such as inadequate physical
activity, dyslipidemia, hypertension, and diabetes mellitus
were signiﬁcantly associated with higher pharmaceutical
expenditures of $519, $631, $1078, and $2006, respectively,
compared with adults without the respective risk factors, after
accounting for sociodemographic factors and comorbidity. In
addition, we found signiﬁcantly higher pharmaceutical expenditures (all medications, CVD-speciﬁc medications, and nonCVD pharmaceutical expenditures) associated with poor
cardiovascular MRF proﬁles among persons with established
ASCVD in a nationally representative cohort, after accounting
DOI: 10.1161/JAHA.116.004996

for underlying comorbid conditions. The adjusted average
annual pharmaceutical expenditure was highest among those
with a poor MRF proﬁle ($4516) and lowest for those with an
optimal MRF proﬁle ($1400).
Another signiﬁcant ﬁnding of our study is that although the
study population consisted of those with established ASCVD,
non-CVD medications contributed the most toward total
pharmaceutical cost. This is comparable to the ﬁndings of the
Cooper Center Longitudinal Study by Willis et al, in which they
reported that average annual non-CVD healthcare cost was
higher than CVD-related healthcare cost and that overall cost
increased with worsening MRF proﬁle.30 These ﬁndings are
not unexpected considering the complex interplay among
CVD, MRFs, and associated comorbidities31 in increasing
healthcare resource utilization and cost.
Some studies have demonstrated an association between
comorbidity and healthcare costs.32–34 In our study, comorbidity was found to be associated with higher pharmaceutical
expenditure among people with established ASCVD. Beyond
that, our study also demonstrated that the burden of
cardiovascular MRF may have a higher impact on pharmaceutical expenditure than the burden of other comorbid
conditions among those with ASCVD. The marginal
Journal of the American Heart Association
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with higher pharmaceutical expenditures and scientiﬁc selection of statistical models using Akaike’s criteria, there may be
unobserved characteristics that affect the outcomes studied,
causing residual confounding; factors such as health insurance, clinicians, pharmacists, healthcare organization, drug
companies, and even patient behaviors are important determinants of pharmaceutical expenditures that could not be
assessed in this study.

Conclusion
Some individual MRFs and worsening MRF proﬁles among
persons with established ASCVD are associated with a higher
annual pharmaceutical expenditure. Future studies are
needed to demonstrate whether patient-centered pragmatic
approaches to manage and prevent MRFs will curtail the rising
pharmaceutical expenditures (on all medications and CVDspeciﬁc medications) among those with ASCVD.
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SUPPLEMENTAL MATERIAL

Table S1. ICD-9 CM codes of diseases classified as ASCVD, and Multum Lexicon Drug Codes for CVD, Diabetic, and other Major Medication Classes
PANEL A
ICD-9-CM
Code

Disease description

410

Acute myocardial infarction

413

Angina pectoris

414

Other forms of chronic ischemic heart disease:

PANEL B
Multum
Lexicon Drug
Code (s)

Drug description

CVD Medications
41-44, 47-49,
53, 55, 56
Anti-hypertensive agents
46

Anti-arrhythmic agents

414

Coronary atherosclerosis

45

Anti-angina agents

414.1

Aneurysm and dissection of heart

19

Antihyperlipidemic agents

414.2

Chronic total occlusion of coronary artery

81

Coagulation modifiers

Coronary atherosclerosis due to lipid rich plaque

40†

Other CVD Medications

414.3

Non-CVD
Medications

414.4

Coronary atherosclerosis due to calcified coronary lesion

414.8

Other specified forms of chronic ischemic heart disease

99

Antidiabetic drugs

414.9

Chronic ischemic heart disease, unspecified

242

Psychotherapeutic drugs

Non-CVD Medications

433

Pre-cerebral occlusion

57

Central Nervous System drugs

434

Cerebral artery occlusion

122

Respiratory System drugs

435

Transient cerebral ischemia

87

Gastrointestinal System drugs

436

Cerebrovascular accident

254

Immunologic drugs

437

Other cerebrovascular disease

20

Anti-Neoplastic drugs

440

Atherosclerosis

443

Other peripheral vascular diseases:

447

Other arterial diseases

447

Other arterial diseases

1
192, 194,
270
98, 100, 103,
217, 295

Anti-infective drugs
Rheumatologic drugs
Hormones and endocrine drugs (excluding anti-diabetic drugs)

Abbreviations: ASCVD, Atherosclerotic Cardiovascular Diseases; CVD, Cardiovascular Disease; ICD-CM, International Classification of Diseases, 9th Revision, Clinical Modification; ACE, Angiotensin
Converting Enzymes
†Excluding

the antihypertensive, anti-arrhythmic, and anti-angina drugs.

Table S2. Charlson Comorbidity Index (CCI) Scoring System
Score
Condition
1 Myocardial Infarction **
Congestive heart failure
Peripheral vascular disease **
Cerebrovascular disease **
Chorionic pulmonary disease
Dementia
Connective tissue disease
Peptic ulcer disease
Mild liver disease (without portal hypertension)
Diabetes (without end-organ damage) **
2 Diabetes (with end-organ damage) **
Hemiplegia
Renal disease (moderate or severe)
Tumor (without metastasis)
Leukemia (acute or chronic)
Lymphoma
3 Liver illness (moderate or severe)
6 Tumor, with metastasis
AIDS
** Diseases excluded from our modified CCI

Table S3. Socio Demographic Characteristics of Adults Aged 40 years
and Older living with ASCVD, MEPS 2012-2013

No. of Survey
Participants
Overall

4,248

US
Population
Equivalent
(Million)

Proportion
(%)

21.9

100.00%

8.5

38.8%

6.2

28.3%

7.2

32.9%

12.1

55.2%

9.8

44.8%

16.4

75.1%

2.5

11.4%

0.5

2.5%

1.9

8.8%

0.5

2.1%

3.3

15.2%

5.3

24.2%

6.1

27.9%

7.2

32.7%

14.8

67.5%

4.5

20.4%

2.7

12.1%

Age group (yrs)
40-64
65-79
>=80

1,647
1,203
1,398

Sex
Men
Women

2,345
1,903

Race/ethnicity
Non-Hispanic White
Non-Hispanic Black
Asian
Hispanic
Other

3,191
485
107
375
90

Family income level*
<100%
100-200%
200-400%
>400%

646
1,027
1,185
1,390

GCCI
0
1
2

2,866
867
515

Abbreviations: Atherosclerotic Cardiovascular Diseases; MEPS, Medical
Expenditure Panel Survey; GCCI, Grouped Charlson Comorbidity Index
* Family Income expressed as a proportion of the Federal Poverty Level

Table S4. Prevalence of Modifiable Risk Factor Profile Across Socio-demographic characteristics of Adults
Aged ≥40 years living with ASCVD , MEPS 2012-2013
Prevalence % (95% CI)
No. of
Survey
Participants
Overall

4,248

Optimal MRF
[0-1 MRF]

Average MRF
[2-3 MRFs]

Poor MRF
[≥4 MRFs]

10.4 (9.0-11.8)

49.9 (47.7-52.2)

39.7 (37.5-42.0)

P value†

Age group (Yrs)
40-64

1,647

11.7 (9.7-14.0)

45.0 (42.0-48.0)

43.3 (40.2-46.5)

65-79

1,203

9.1 (6.7-12.1)

48.3 (44.5-52.1)

42.7 (38.9-46.5)

>=80

1,398

9.9 (7.5-13.0)

57.2 (52.8-61.5)

32.9 (28.7-37.3)

Men

2,345

9.4 (7.7-11.5)

50.8 (47.8-53.7)

39.8 (36.8-42.9)

Women

1,903

11.5 (9.4-13.9)

48.9 (45.8-52.0)

39.6 (36.6-42.7)

Non-Hispanic White

3,191

11.0 (9.4-12.9)

51.3 (48.5-54.0)

37.7 (35.1-40.3)

Non-Hispanic Black

485

6.6 (4.9-8.7)

45.6 (41.4-49.8)

47.9 (43.5-52.2)

Asian

107

13.0 (8.1-20.3)

57.8 (47.5-67.5)

29.2 (21.0-38.9)

Hispanic

375

9.4 (7.2-12.2)

45.7 (40.9-50.5)

44.9 (40.2-49.7)

Other

90

7.4 (2.5-20.0)

33.4 (21.6-47.9)

59.2 (45.6-71.5)

646

8.2 (5.9-11.3)

44.1 (39.2-49.1)

47.7 (42.9-52.6)

100-200%

1,027

8.0 (6.0-10.6)

50.5 (46.6-54.5)

41.4 (37.8-45.2)

200-400%

1,185

9.2 (6.9-12.1)

50.4 (45.7-55.1)

40.4 (36.1-44.9)

>400%

1,390

14.1 (11.5-17.2)

51.8 (47.8-55.8)

34.1 (30.1-38.3)

0

2,866

12.1 (10.5-13.9)

52.4 (49.9-54.8)

35.6 (33.0-38.2)

1

867

9.0 (6.0-13.4)

42.7 (38.1-47.4)

48.3 (44.152.5)

2

515

3.1 (1.6-5.7)

48.6 (42.4-54.9)

48.3 (41.8-54.8)

0.0002

Sex
0.8542

Race/ethnicity

<0.001

Family income level*
<100%

<0.001

GCCI

<0.001

Abbreviations: ASCVD, Atherosclerotic cardiovascular Disease; MEPS, Medical Expenditure Panel Survey; CI,
Confidence Interval; GCCI, Grouped Charlson Comorbidity Index
* Family Income expressed as a proportion of the Federal Poverty Level
† χ2 Statistic used to test difference in proportions between respondents

Figure S1. Flow Chart Showing the Study Population Selection, MEPS 2012-2013

Figure S2. Mean Healthcare Expenditure Across MRF Profile and Charlson Comorbidity Index
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